NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals
NexTel Medical (MAJI) announced plans to launch a wellness product line incorporating FDA-approved active pharmaceutical ingredients, with alternative administration methods.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NexTel Medical (MAJI) announced plans to launch a wellness product line incorporating FDA-approved active pharmaceutical ingredients, with alternative administration methods.
The initial commercial rollout is scheduled to begin in the second quarter of 2027. NexTel says its delivery formulations are designed to improve bioavailability—the amount of medication available to the body—and offer alternatives to traditional subcutaneous injections. The FDA-approved status described applies to the active ingredients incorporated into the planned products.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, FL / ACCESS Newswire / October 7, 2026 / NexTel Medical Corp. (OTCID:MAJI) ("NexTel" or the "Company"), a clinical-stage biotechnology leader pioneering proprietary exosome-based delivery systems and diagnostic technologies, today announced plans to launch a new, next-generation line of wellness products incorporating FDA-approved active pharmaceutical ingredients.
Industry security analysts and healthcare intelligence groups estimate the overall unregulated market for peptides and metabolic therapies at
NexTel's upcoming product line will leverage advanced delivery formulations designed to significantly enhance bioavailability while removing common barriers to adherence-most notably the reliance on traditional subcutaneous injections. By providing non-invasive, highly effective alternative administration methods for established, FDA-approved medications, NexTel aims to capture market share from traditional formulations and broaden overall patient adoption.
"Our mission is to bridge the gap between clinical efficacy and patient convenience," said Matthew Dwyer, CEO of NexTel Medical Corp. "A vast number of patients who could benefit from these proven therapies hesitate due to needle aversion or suboptimal oral delivery options. By applying our novel delivery formulations to established, FDA-approved compounds, we are providing a safer, more effective alternative to the pervasive unverified 'research-only' products in the market. We anticipate streamlined customer acquisition dynamics as we introduce superior administration methods into a proven, high-demand therapeutics sector."
The initial commercial rollout of the new wellness product line is scheduled to commence in the second quarter of 2027.
About NexTel Medical Corp.
NexTel Medical Corp. (OTCID:MAJI) is a pioneering biotechnology leader at the forefront of exosome research, clinical diagnostics, and accessible healthcare solutions. The Company specializes in developing proprietary, next-generation exosome delivery systems and non-invasive screening tools designed to revolutionize therapeutic and diagnostic modalities. NexTel's integrated platform bridges complex biotechnology innovations with scalable market delivery:
- Maxasome Health Check: Proprietary, non-invasive liquid biopsy diagnostics utilizing the NANOG DNA assay for universal early-stage cancer screening.
- Maxasome™ PLUS: Next-generation, high-bioavailability therapeutics powered by
100% pure exosomal delivery systems.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. NexTel Medical Corp's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of NexTel Medical Corp., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
NexTel Medical Corp.
ir@nexTelmedical.com
X: @NexTelMedical
SOURCE: NexTel Medical Corp
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does NexTel Medical (MAJI) plan to launch its wellness product line?
The initial commercial rollout is scheduled to begin in the second quarter of 2027. The planned line will incorporate FDA-approved active pharmaceutical ingredients using alternative administration methods.